Sutent
(Sunitinib)
(50 mg)
(fourteen)
(Tablets)
Sutent (sunitinib) 50 mg 14 tabs PFIZER Italy
Article:
In Stock
Indications:
- Metastatic renal cell carcinoma (MRC).
- Sutent is indicated for the treatment of advanced and/or metastatic renal cell carcinoma.
- Stromal tumors of the digestive tract (SPTT).
- Gastrointestinal stromal tumors (SPTT) following failure of treatment with imatinib mesilate due to resistance or intolerance.
- Neuroendocrine tumors of the pancreas (NSAIDs).
- Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults. There is limited experience with Sutent as a first-line treatment. Misha95
- 8kar7unknown
-
Commercial name:Sutent
-
Сhemical name:Sunitinib
-
Dosage:50 mg
-
Quantity:fourteen
-
Release form:Tablets
-
Производитель:Pfizer
No reviews yet